Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
reports
Verrica Pharmaceuticals (VRCA) Stock Price & Analysis
259 Followers
VRCA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.77 - $9.22
Previous Close$4.62
Volume576.83K
Average Volume (3M)115.51K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$39.45M
Total Debt (Recent Filing)$1.59M
Price to Earnings (P/E)-4.5
Beta1.40
Next EarningsMar 02, 2023
EPS Estimate-$0.19
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$7.50
EPS (TTM)-1.02
Shares Outstanding41,094,053
R-Squared0.22
Standard Deviation0.24
10 Day Avg. Volume191,807
30 Day Avg. Volume115,511
Price to Book (P/B)3.91
Price to Sales (P/S)19.02
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-12.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside50.60% Upside
Rating ConsensusModerate Buy
Alpha-0.02
Number of Analyst Covering3
Verrica Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $1.77 and its highest was $9.22 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Currently, no data Available
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Mar 02, 2023 which is in 27 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Nov 07, 2022. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.105.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -$0.19.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 41,094,050 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of $0 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went down -6.723%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Among the largest hedge funds holding Verrica Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Verrica Pharmaceuticals’s shares valued at 15M.
---
Verrica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50
$7.50
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.81%
12-Months-Change
Fundamentals
Return on Equity
-65.63%
Trailing 12-Months
Asset Growth
-44.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
---
---